Praxis Precision Medicines (PRAX) Q3 2026 earnings review
Praxis builds its sales teams, but a follow-on trial slips
Praxis Precision Medicines, a biotechnology company developing drugs for brain disorders, is spending heavily to hire sales teams ahead of two FDA approval decisions. Administrative costs more than tripled from a year ago to $43 million as chief executive Marcio Souza finished hiring the commercial team for its rare childhood epilepsy drug, relutrigine. Net cash fell by $88 million in the quarter to $1.3 billion by our math, inside what the prior burn pace pointed to.
| Cash and marketable securities | $1.29B down $88M from last quarter by our math |
|---|---|
| Administrative and launch expenses | $42.7M up 240% from a year ago |
| Net loss | $94.2M $73.9M a year ago |
| Lead FDA target decision dates | Unchanged Dec 27, 2026 and Jan 29, 2027 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because both lead FDA review dates held firm for late December and late January while launch preparations stayed on track. One caution: the company delayed its POWER3 trial for its follow-on epilepsy drug vormatrigine into 2027 and stayed silent on early-stage genetic drug nominations due this year.
The question now is whether the FDA approves both lead drugs with prescribing labels that let doctors use them easily, and whether relutrigine works in a broader group of childhood epilepsies. Clean approvals and a positive EMERALD trial readout would open two large commercial markets, while restrictive dosing rules on ulixacaltamide would slow patient uptake. The EMERALD results this quarter and the FDA decisions on December 27 and January 29 will settle it.
🐂 Bull Case
Sales Teams Take Shape Ahead of Two Drug Decisions
Praxis Precision Medicines develops drugs for brain and nervous system disorders and does not yet sell any approved products. Its two lead drug applications remain on schedule at the Food and Drug Administration (FDA). Regulators plan to rule on relutrigine, a treatment for rare childhood genetic epilepsies (SCN2A and SCN8A developmental and epileptic encephalopathies, or DEEs), by December 27, 2026.
A second decision on ulixacaltamide, a pill for essential tremor (an involuntary shaking disorder affecting seven million Americans), follows on January 29, 2027. Chief executive Marcio Souza said that "The relutrigine team is fully hired, and we expect the ulixacaltamide sales force to be in place this quarter." The drugmaker also "reinitiated the long-term safety study (LTSS) associated with the Essential3 program to provide an opportunity for eligible patients to participate ahead of potential commercial availability".
Meanwhile, its EMERALD trial testing relutrigine across a broader group of childhood epilepsies is in its final stages for a fourth-quarter readout. Having sales reps hired and patients back on treatment before approval matters because it lets the Boston-based biotech start billing insurers immediately if regulators clear the drugs.
What to watch: the FDA decision on relutrigine on December 27, 2026, alongside fourth-quarter results from the EMERALD study. Approval and positive trial data would open both the initial rare epilepsy market and a much larger group of childhood seizure disorders.
🐻 Bear Case
Common Epilepsy Trial Delays Again After Earlier Miss
Behind its two lead drugs, Praxis is developing vormatrigine, a daily pill for adult focal onset seizures and common generalized epilepsy. In June, vormatrigine missed the main goal in its first late-stage study, POWER1, which management blamed on fixable trial design issues. Last quarter, Souza told investors that both follow-up trials, POWER2 and POWER3, would run by the fourth quarter of 2026.
This quarter delivered only half of that plan. While "The POWER2 study has restarted following updates to the study design, which incorporate key learnings from the POWER1 Phase 2/3 study", the biotech "continues to review the study design of POWER3, its planned study of vormatrigine as a monotherapy, and expects to initiate in 2027". Furthermore, the release said nothing about nominating early-stage genetic drug candidates (PRAX-080, PRAX-090 and PRAX-100) that management previously slated for 2026.
Pushing POWER3 into 2027 marks the second delay for that study, which the group first planned to start in the first half of 2026. That delay cuts against management's claim that the POWER1 setback required only a quick adjustment.
What to watch: the updated trial design for POWER2 and POWER3 at the Investor Day on November 12, 2026. Further changes to dosing or patient selection would show that vormatrigine faces deeper clinical hurdles than a simple protocol tweak.
Launch Hiring Triples Administrative Costs
Building two commercial sales teams at the same time is driving a sharp rise in overhead before any product money comes in. General and administrative expenses — the cost of sales reps, marketing and corporate overhead — more than tripled from a year ago to $42.7 million.
- Administrative expenses: $42.7 million, up 240% from a year ago and up 55% from last quarter
- Administrative personnel costs: up $17.2 million from a year ago as sales hiring ramped
- Outside professional fees: up $9.4 million from a year ago for launch preparations
- Cash and marketable securities: $1,286 million, down $88 million from June 30 by our math
Even with $1.3 billion in the bank, Praxis says its funds "maintain runway into 2028". By our math, exhausting that cash over the six quarters to early 2028 implies quarterly cash burn rising above $200 million, more than double this quarter's $88 million net cash drop.
What to watch: fourth-quarter administrative expenses and any 2027 spending budget shared at the November 12 Investor Day. A steeper cost ramp would leave less cushion if insurer coverage slows early drug sales.
Risks this quarter didn't answer
Because management stops providing regulatory updates ahead of FDA decision dates and has not yet reported fourth-quarter trial data, four major risks saw no new evidence in the third-quarter release.
- FDA approval decisions: both relutrigine and ulixacaltamide face binary regulatory rulings on December 27, 2026 and January 29, 2027.
- Ulixacaltamide prescribing label and patient drop-off: about 30% of trial patients had early side effects, and how the FDA writes the dosing instructions or Drug Enforcement Administration scheduling will only become clear upon approval in January.
- EMERALD study across diverse epilepsies: whether relutrigine works across more than 50 different genetic causes of epilepsy awaits the fourth-quarter readout.
- Insurer hurdles at launch: whether health plans force essential tremor patients to try cheap generic propranolol before paying for ulixacaltamide will be tested after the first quarter of 2027.
👓 Other Themes
High Interest Rates Cushion Operating Losses
Higher interest earnings on the company's $1.3 billion treasury pile helped offset a wider operating loss this quarter. Other income — mostly interest earned on marketable securities after two large stock offerings in late 2025 and early 2026 — nearly tripled from a year ago to $12.7 million, keeping the net loss at $94.2 million against an operating loss of $106.9 million.
💲 Other KPIs
Research and development spending — the cost of running clinical trials and lab studies — fell 2.4% from a year ago and 7.5% from last quarter. Spending on the Cerebrum small-molecule pill platform dropped by $8.8 million as late-stage trials for ulixacaltamide wound down, which more than offset a $7.0 million rise in research staff pay.
The average share count jumped 32.8% from a year ago after the biotechnology group sold stock in October 2025 and January 2026 to fund its drug launches. Because those extra shares spread the loss over a wider base, net loss per share shrank 3.9% to $3.23 even though total net loss widened by 27.5%. Stock-based compensation also doubled to $14.9 million.
🔮 Guidance
Unchanged. Praxis expects its $1.29 billion in cash and marketable securities to fund operations into 2028. Management has kept this same 2028 target since late 2024 despite raising nearly $1.2 billion in new stock. By our math, running out of cash by early 2028 implies quarterly spending will more than double from this quarter's $88 million cash drop as two drug launches begin.
Unchanged. The FDA target decision date for relutrigine in SCN2A and SCN8A childhood epilepsies holds at December 27, 2026, following last quarter's three-month extension. The EMERALD trial in broader genetic epilepsies is in its final stages of completion, and the company still plans to report topline results in the fourth quarter of 2026.
Unchanged. Regulators remain set to rule on ulixacaltamide for essential tremor by January 29, 2027. Management plans to finish hiring the field sales team in the fourth quarter of 2026 so reps are ready before the FDA action date.
Cut. The drugmaker pushed the start of its POWER3 standalone trial for vormatrigine from the fourth quarter of 2026 into 2027 while it continues to review the study design. This is the second delay for POWER3, which management originally slated for the first half of 2026 before the POWER1 trial missed its primary goal.
Unchanged. Enrollment in the registrational EMBRAVE3 study of elsunersen — a genetic therapy for early-onset SCN2A epilepsy developed under the Solidus platform — continues to advance toward topline results in 2027.
❓ Key Questions
Why did the POWER3 monotherapy study slip into 2027?
Last quarter management planned to have both POWER2 and POWER3 running by the fourth quarter of 2026. Only POWER2 restarted, while POWER3 remains under design review, raising questions about what hurdle held back the standalone epilepsy trial.
What happened to the 2026 early-stage genetic drug nominations?
Praxis previously planned to name development candidates for PRAX-080, PRAX-090 and PRAX-100 in 2025, then the first half of 2026, and then 2026. The third-quarter release dropped any mention of those candidates.
What quarterly launch spending does the 2028 runway assume?
With $1.29 billion in cash and an $88 million quarterly cash drop, a runway that ends in 2028 implies quarterly spending will more than double. Investors need the exact 2027 launch budget at the November 12 Investor Day.
How many patients rejoined the Essential3 safety study?
The company reopened its long-term safety study for ulixacaltamide so eligible essential tremor patients can take the drug before commercial launch. The number of returning patients will show early demand and real-world tolerability.